Allstate Investment Management’s Royalty Pharma RPRX Stock Holding History

Allstate Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$523K	Buy	+13,238	New	+$553K	0.02%	487

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allstate Investment Management's RPRX Position: Q4 2022 in Review

Allstate Investment Management opened a new position in Royalty Pharma (RPRX) in Q4 2022: 13,238 shares worth $523K. The stake represents 0.02% of the portfolio and ranks #487 among its holdings.

334 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

Allstate Investment Management held 13,238 shares of Royalty Pharma worth $523K as of Q4 2022.
Royalty Pharma was a new Allstate Investment Management position in Q4 2022.
Royalty Pharma made up 0.02% of Allstate Investment Management's portfolio in Q4 2022, its #487 holding.
334 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.